Harpoon Therapeutics has promoted Holger Wesche to chief scientific officer. Wesche had been senior vice president, research, of the South San Francisco, CA-based cancer immunotherapy developer. Harpoon also named Georgia Erbez its chief financial officer. Erbez was most recently chief business officer and CFO of Zosano Pharma (NASDAQ: ZSAN). The executive moves follow Harpoon’s appointment of Natalie Sacks to the chief medical officer post earlier this month. Harpoon’s lead drug, HPN424, is in early-stage clinical testing as a treatment for prostate cancer.